Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma
Affiliations: Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, P.R. China
- Published online on: May 7, 2019 https://doi.org/10.3892/ol.2019.10331
Copyright: © Zhou
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The aim of the present study was to investigate the expression of microRNA (miR)‑338‑5p in retinoblastoma(RB), thereby evaluating whether it could have potential as a biomarker to screen patients with RB from healthy controls. The results revealed that miR‑338‑5p was significantly upregulated in patients with RB compared with in healthy controls. There was no significant difference in the expression of miR‑338‑5p between patients with RB of different age, sex, tumor stage or binocular disease. Receiver operator characteristic analysis indicated that serum miR‑338‑5p combined with neuron‑specific enolase (NSE) had a larger area under the curve compared with serum miR‑338‑5p alone when diagnosing RB. In addition, suppression of miR‑338‑5p induced slower proliferation of ACBRI‑181 and Y79 cells at 2, 3, 4 and 5 days compared with the negative control group. Flow cytometric analysis indicated that transfection with miR‑338‑5p inhibitor leads to significant cell cycle arrest in ACBRI‑181 and Y79 cells compared with in the negative control group. Furthermore, transfection with miR‑338‑5p inhibitor significantly decreased ACBRI‑181 and Y79 cell migration and invasion, suggesting that miR‑338‑5p may serve an oncogenic role in the progression of RB. In conclusion, the low expression of miR‑338‑5p in the serum of patients with RB suggests that it may be involved in the formation of RB. Serum miR‑338‑5p has the potential to be a tumor marker of RB, and, in combination with NSE, miR‑338‑5p may improve the early diagnosis rate of RB.